Johnson & Johnson has appointed Tom Cavanaugh as Executive Vice President, Worldwide Chairman Innovative Medicine. Cavanaugh has been with Johnson & Johnson for almost a decade and currently serves as Company Group Chairman, North America, Innovative Medicine. Cavanaugh brings nearly three decades of biopharmaceutical experience and leadership across therapeutic areas, functions and geographies to the role and will join the Johnson & Johnson Executive Committee, effective as of 1 September 2026. Cavanaugh joined Johnson & Johnson in 2017 and has held senior leadership positions in Oncology, Immunology and Global Commercial Strategy. Cavanaugh succeeds Jennifer Taubert, who will retire from her position as Executive Vice President, Worldwide Chairman, Innovative Medicine after more than 21 years at Johnson & Johnson.